[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354780-105":59,"doc-detail-354780-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","association-of-cancer-antigen-15-3-with-distant-recurrence-in-immunohistochemically-defined-breast-cancer-subtypes-in-canadian-cancer-trials-group-ma32","Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32","","Background: Circulating cancer antigen (CA) 15-3 has been linked to distant breast cancer recurrence, yet subtype-specific evidence is limited. Methods: In MA.32, 3649 participants with T1-3, N0-1, M0 breast cancer were randomized; 2740 provided blood at entry (mean 278 days) and at 6 months. Baseline and 6-month CA 15-3 associations with distant recurrence-free survival were tested across luminal, triple-negative, and HER2-positive subtypes using Cox models. Results and Conclusion summarized overall associations and subtype differences.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/association-of-cancer-antigen-15-3-with-distant-recurrence-in-immunohistochemically-defined-breast-cancer-subtypes-in-canadian-cancer-trials-group-ma32/354780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/association-of-cancer-antigen-15-3-with-distant-recurrence-in-immunohistochemically-defined-breast-cancer-subtypes-in-canadian-cancer-trials-group-ma32/354780.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study designed to evaluate regarding CA 15-3?","Question",{"text":112,"@type":113},"The study evaluated how baseline CA 15-3 levels and the 6-month change in CA 15-3 relate to distant recurrence-free survival across breast cancer subtypes defined by immunohistochemistry.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were participants selected and what measurements were taken?",{"text":117,"@type":113},"In MA.32, 3649 participants with T1-3, N0-1, M0 breast cancer were randomized, and 2740 provided blood at entry and again 6 months later for CA 15-3 assessment.",{"name":119,"@type":110,"acceptedAnswer":120},"Did CA 15-3 at study entry predict distant recurrence outcomes?",{"text":121,"@type":113},"No; CA 15-3 at study entry was not associated with outcomes in any breast cancer subtype examined.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354780,1790174140,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","JNCI Cancer Spectrum, 2026, 10(5), pkag068  \n[https://doi.org/10.1093/jncics/pkag068](https://doi.org/10.1093/jncics/pkag068)  \nAdvance Access Publication Date: June 25, 2026  \nArticle  \nAssociation of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32  \nPamela J. Goodwin , MD􀀃 ,1, Bingshu E. Chen , PhD2, Karen A. Gelmon, MD3, Timothy J. Whelan, BM, BCh4, Marguerite Ennis , PhD5, Jennifer Ligibel, MD6, Paul M. Stos, BSc (Hon)7, Lois E. Shepherd, MD8, Wendy R. Parulekar, MD9, Vuk Stambolic, PhD10  \n1Department of Medicine and Lunenfeld-Tanenbaum Research Institute, Sinai Health System, University of Toronto, Toronto, ON, Canada 2Canadian Cancer Trials Group, Department of Public Health Sciences, Queens University, Kingston, ON, Canada  \n3Department of Medical Oncology, BC Cancer Agency and Department of Medicine, University of British Columbia, Vancouver, BC, Canada 4Department of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, ON, Canada  \n5Applied Statistician, Markham, ON, Canada  \n6Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard University, Boston, MA, United States 7Trial Management Group, Faculty of Health Sciences, Queens University, Kingston, ON, Canada  \n8Canadian Cancer Trials Group, Department of Pathology and Molecular Medicine, Queens University, Kingston, ON, Canada 9Canadian Cancer Trials Group, Departments of Oncology and Medicine, Queens University, Kingston, ON, Canada  \n10Princess Margaret Cancer Center, University Health Network and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada  \n􀀃 Corresponding author: Pamela J. Goodwin, MD, Department of Medicine, Mount Sinai Hospital, 1085-600 University Ave, Toronto, Canada M5G 1X5 ([pgoodwin@lunenfeld.ca](pgoodwin@lunenfeld.ca)) .  \nAbstract  \nBackground: Circulating levels of cancer antigen (CA) 15-3 have been associated with distant breast cancer recurrence; data on breast cancer subtypes are sparse. We examined associations of CA 15-3 with outcomes across immunohistochemically defined breast cancer subtypes in MA.32 .  \nMethods: A total of 3649 participants with T1-3, N0-1, M0 breast cancer were randomly assigned; 2740 (75.1%) provided blood at entry (mean ¼ 278 days postdiagnosis) and 6 months later. Prognostic associations of baseline and 6-month change in CA 15-3 with distant recurrence-free survival (RFS) were examined in luminal (estrogen receptor–positive and/or progesterone receptor–positive, HER2-negative), triple-negative (estrogen receptor, progesterone receptor, HER2 negative) and HER2-positive (any estrogen receptor, progesterone receptor) breast cancer using Cox proportional hazards models.  \nResults: Mean age was 52 years. Breast cancer was luminal in 1589 (58.7%), triple negative in 655 (24.2%), and HER2 positive in 464 (17.1%) participants. Median follow-up was 96 months. CA 15-3 at study entry was not associated with outcome in any subtype. Rising CA 15-3 at 6 months was associated with poor distant RFS in luminal and triple-negative breast cancer (hazard ratio [HR] per 25% increase ¼ 1.41, P \u003C .0001, and HR ¼ 1.35, P \u003C .0001, respectively) . New elevations in CA 15-3 at 6 months were adversely associated with distant RFS in those with luminal or triple-negative breast cancer (HR ¼ 4.14, 95% CI ¼ 2.69 to 6.38; P \u003C .001; and HR ¼ 3.57, 95% CI ¼ 1.59 to 7.99; P ¼ .002, respectively). In HER2-positive breast cancer, CA15-3 was not associated with distant RFS.  \nConclusion: Rising CA 15-3 was associated with reduced distant RFS in luminal and triple-negative breast cancer but not in HER2-positive breast cancer.  \nClinical Trial Registration: [ClinicalTrials.gov](ClinicalTrials.gov) NCT01101438  \nIntroduction  \nElevated circulating levels of cancer antigen (CA) 15-3 have been associated with an increased risk of distant recurrence in breast cancer. In an American Society of Clinical Oncology (ASC","cbCaihTh2xjNyAEU","https://ap.wps.com/l/cbCaihTh2xjNyAEU","pdf",991533,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What was the study designed to evaluate regarding CA 15-3?\",\"answer\":\"The study evaluated how baseline CA 15-3 levels and the 6-month change in CA 15-3 relate to distant recurrence-free survival across breast cancer subtypes defined by immunohistochemistry.\"},{\"question\":\"How were participants selected and what measurements were taken?\",\"answer\":\"In MA.32, 3649 participants with T1-3, N0-1, M0 breast cancer were randomized, and 2740 provided blood at entry and again 6 months later for CA 15-3 assessment.\"},{\"question\":\"Did CA 15-3 at study entry predict distant recurrence outcomes?\",\"answer\":\"No; CA 15-3 at study entry was not associated with outcomes in any breast cancer subtype examined.\"}]","Association of cancer antigen 15-3 with distant recurrence in immunohistochemically defined breast cancer subtypes in Canadian Cancer Trials Group MA.32 | PDF",1790113811,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cf24146bfc6111e415b2dcf6083ed2a.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/566020711a4a052bb136614e5d1b70cd.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2900c9c43a672281c1e4d00b9dc0c47.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3206cabf749a074f16f272785a691dd3.webp",980,1287]